Radionuclide Archives

16 Nov 2025

0 Comments

MP0712 (212Pb x DLL3), Radio-DARPin – DLL3 Radioligand Therapy Trial for Neuroendocrine Neoplasms

Clinical Trials and ResearchDLL3, extra, High grade neuroendocrine neoplasm (NEN), Neuroendocrine carcinoma (NEC), Peptide receptor radionuclide therapy (PRRT), PET Scan, Radioligand, Radioligand therapy, Radionuclide, Small cell lung cancer (SCLC)

Update 2nd July 2026. First patients dosed. Molecular Partners and Orano Med have dosed the first patients in a US Phase 1/2a trial of MP0712, a novel Radio-DARPin drug targeting DLL3, a protein highly expressed in small cell lung cancer and other neuroendocrine tumors. This therapy uses lead-212 to deliver targeted alpha radiation to tumors, aiming to improve treatment precision and reduce side effects. Initial safety and efficacy data are expected later in 2026, with comprehensive results anticipated in 2027. The trial is ongoing at five US sites, with more centers planned to open this year. What is Radioligand Therapy?…

24 Jan 2025

By Ronny Allan

16 Comments

Neuroendocrine Cancer: Somatostatin Receptor (e.g. Ga68, Cu64) PET Scans – a game changer?

Living with Neuroendocrine Cancer, Survivorship, Treatment64Cu-DOTATATE, Axillary nodes, Bone metastases, CT scan, Degenerative bone disease, Ga68 PET/CT, Liver metastases, NETSPOT, Neuroendocrine cancer, Octreotide scan, Overdiagnosis, Physiological uptake, Radionuclide, Retroperitoneal Fibrosis, SEER, SomaKit TOC, SSTR-PET, Subpectoral lymph node, Supraclavicularfossa (SCF) lymph nodes, Surveillance, Ureter

I was diagnosed in 2010 with metastatic NETs clearly showing on CT scan, the staging was confirmed via an Octreotide Scan which in addition pointed out two further deposits above the diaphragm (one of which has since been dealt with). In addition to routine surveillance via CT scan, I had two further Octreotide Scans in 2011 and 2013 following 3 surgeries, these confirmed the surveillance CT findings of the remnant disease. The third scan in 2013 highlighted an additional lesion in my thyroid (still under a watch and wait regime, biopsy inconclusive - but read on....). In 2018, my 6…

26 Oct 2024

By Ronny Allan

10 Comments

PRRT – The Sequel? Alpha-emitter PRRT for Neuroendocrine Tumours (NET)

Clinical Trials and Research212Pb-AR-RMX, Ac-225, Advanced neuroendocrine cancer, Carcinoid tumour, Incurable cancer, Metastatic Neuroendocrine Cancer, Neuroendocrine, Neuroendocrine cancer, Nuclear medicine, Peptide receptor radionuclide therapy (PRRT), PRRT, Radioimmunotherapy, Radionuclide, Somatostatin analogues, Targeted alpha-emitter therapy (TAT)

Updated and reviewed June 2026. Alpha‑emitter PRRT is emerging as the next major evolution of peptide receptor radionuclide therapy. Instead of using a beta‑emitting isotope such as 177Lu, these new approaches use alpha‑particle–emitting isotopes like 212Pb or 225Ac. The goal is simple: deliver more powerful DNA‑damaging radiation directly into tumour cells while keeping the impact on surrounding tissues as low as possible. This is still experimental, but the science is compelling — and the early clinical signals are strong enough that alpha‑emitter PRRT is now considered one of the most important areas to watch in NET research. How alpha‑emitter PRRT…

31 May 2018

By Ronny Allan

17 Comments

All you need to know about Somatostatin Receptor PET/CT Scans for Neuroendocrine Tumours

Treatment64Cu-DOTATATE, CT scan, Degenerative bone disease, Detectnet, Ga68 PET/CT, Ga68-DOTANOC, Meningioma, NETSPOT, Neuroendocrine cancer, Octreotide scan, Osteoblastic activity, Overdiagnosis, Pancreatic uncinate process, Physiological uptake, Radioligand, Radioligand therapy, Radionuclide, SEER, SomaKit TOC, Splenosis, Splenunculus, SSTR-PET, Surveillance, Vertebral haemangioma

Cancer is a growth industry ...literally! More people are being diagnosed than ever before. Fortunately, more people are surviving than ever before. This is against a backdrop of better awareness, better screening in the big population cancers, and to a certain extent better diagnostic tools, all of which is leading to earlier diagnosis. So how does this affect Neuroendocrine Cancer? According to the latest SEER database figures for Neuroendocrine Cancer, one reason for the 7 fold increase in incidence rates since the 1970s is all of those things above including better diagnostics. This has led to a revised set of…

18 Jan 2017

By Ronny Allan

5 Comments

Theranostics for Neuroendocrine Cancer – A Find and Destroy Mission

Awareness, Clinical Trials and Research, Living with Neuroendocrine Cancer, TreatmentAdvanced neuroendocrine cancer, Edotreotide, Ga68 PET/CT, Indium 111-pentetreotide, Lutathera, Metastatic Neuroendocrine Cancer, NETSPOT, NETTER-1, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nuclear medicine, Octreoscan (Octreotide scan), Octreotide, Pancreatic NET (PanNET), Paraganglioma, Pentetreotide, Peptide receptor radionuclide therapy (PRRT), Pheochromocytoma, PRRT, Radionuclide, Satoreotide (Lutetium-177), SomaKit TOC

Theranostics is a joining of the words therapeutics and diagnostics. You may also see it conveyed as 'Theragnostics' and these terms are interchangeable. The basic aim of theranotistics is to find and then destroy the 'bad guys'. With Neuroendocrine Cancer, finding the tumours (the bad guys) can often be a challenge - they can be small and/or difficult to find - they are sometimes expert at camouflage. Moreover, once found, they can then be difficult to treat (destroy), as they can often prove resistant to conventional cancer drugs and many are inoperable due to sheer quantity, spread and positioning. When…

07 Sep 2015

By Ronny Allan

11 Comments

PRRT and the NHS England Cancer Drugs Fund (now archived information)

TreatmentAfinitor, DOTA-TATE, Everolimus, Gallium 68 (Ga68), Lu-177, Lutathera, Neuroendocrine cancer, Neuroendocrine tumour (NET), Nuclear medicine, Octreotide, Peptide receptor radionuclide therapy (PRRT), Pheochromocytoma, PRRT, Radiolabelled somatostatin analogue, Radionuclide, Yttrium 90 (Y90)

Please note this post is now historic information - PRRT (Lutathera) was eventually approved for use in UK. See the following post for the very latest on PRRT worldwide - CLICK HERE I was extremely disappointed to learn of the decision to remove PRRT (Lutetium or Yttrium) from the Cancer Drugs Fund (CDF). You can read the detail of the decision here: CDF Statement. PRRT has regularly been described by NET specialists and patients as the "magic bullet" due to its potential to shrink or kill tumours. This is the second Neuroendocrine Cancer treatment to be withdrawn this year, after…

Tag: Radionuclide